18 terminated. 18 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 18 | Terminated 18 |
| Phase 2 | 5 | Terminated 5 |
Follow Precursor Cell Lymphoblastic Leukemia-Lymphoma: new trials by email Literature Review of Precursor Cell Lymphoblastic Leukemia-Lymphoma trials Research Report on Precursor Cell Lymphoblastic Leukemia-Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SPARK-ALL: Calaspargase Pegol in Adults With ALL Calaspargase pegol (S95015) - Acute Lymphoblastic Leukemia | Phase 2 / Phase 3 | Terminated | Institut de Recherches Internationales Servier | 42 | 2021-07-07 | 2026-10-29 |
| Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005) Efprezimod alfa, Placebo, Methotrexate - Hematopoietic Stem Cell Transplantation, Acute Graft Versus Host Disease | Phase 3 | Terminated | Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 11 | 2021-01-05 | 2023-02-08 |
| Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer ATIR101, Cyclophosphamide, T-cell depleted HSCT from a related, haploidentical donor - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 3 | Terminated | Kiadis Pharma | 63 | 2017-11-29 | 2022-05-24 |
| Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) Blinatumomab, Standard of Care Chemotherapy - Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | Phase 3 | Terminated | Amgen | 405 | 2014-01-03 | 2024-03-05 |
| Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis ARM A Cyclophosphamide, ARM B Calcineurin inhibitor and methotrexate - Acute Myelogenous Leukemia, Acute Lymphoid Leukemia | Phase 3 | Terminated | Hospital Israelita Albert Einstein | 3 | 2012-12-01 | 2017-03-03 |
| A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL Vincristine Sulfate Liposomes Injection (VSLI), Vincristine Sulfate Injection (VSI) - Acute Lymphoblastic Leukemia (ALL) | Phase 3 | Terminated | Spectrum Pharmaceuticals, Inc | 26 | 2012-03-01 | 2021-09-09 |
| PROCEDYTE: Depocyte® Administration (Liposomal Cytarabine) as Prophylaxis of Neuromeningeal Infiltration in Acute Lymphoblastic Leukemia DepoCyte - Acute Lymphoblastic Leukemia | Phase 3 | Terminated | PETHEMA Foundation | 7 | 2009-09-01 | 2015-05-08 |
| Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor Donor lymphocyte preparation depleted of host functional alloreactive T-cells - Myeloid Leukemia, Lymphoblastic Leukemia | Phase 2 / Phase 3 | Terminated | Kiadis Pharma | 40 | 2009-08-01 | 2021-06-14 |
| Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant moxifloxacin hydrochloride, Placebo - Breast Cancer, Chronic Myeloproliferative Disorders | Phase 3 | Terminated | OHSU Knight Cancer Institute | 240 | 2006-05-01 | 2017-05-09 |
| Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD) mycophenolate mofetil, placebo - Cancer | Phase 3 | Terminated | Martin, Paul | 151 | 2004-05-01 | 2013-05-03 |
| Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia (ALL) Insulin Glargine, Insulin Aspart - Leukemia, Lymphoma | Phase 3 | Terminated | M.D. Anderson Cancer Center | 52 | 2004-04-01 | 2015-06-03 |
| Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma CHOP regimen, EPOCH regimen, cyclophosphamide - Lymphoma | Phase 2 / Phase 3 | Terminated | European Organisation for Research and Treatment of Cancer - EORTC | 3 | 2003-03-01 | 2012-09-24 |
| Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS) Mylotarg - Leukemia | Phase 2 / Phase 3 | Terminated | M.D. Anderson Cancer Center | 3 | 2001-05-01 | 2018-10-31 |
| Stem Cell Transplantation for Hematological Malignancies Stem Cell Transplant, Busulfan, Cyclophosphamide - Leukemia, Lymphocytic, Acute, AML | Phase 2 / Phase 3 | Terminated | Masonic Cancer Center, University of Minnesota | 11 | 2000-06-07 | 2017-12-05 |
| Total Therapy Study XIV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia Prednisone, Dexamethasone, Vincristine, Daunorubicin, PEG-L-asparaginase, L-asparaginase, Methotrexate, Idarubicin, Etoposide, Cyclophosphamide, Cytarabine, Mercaptopurine - Acute Lymphoblastic Leukemia | Phase 3 | Terminated | St. Jude Children's Research Hospital | 53 | 1998-07-01 | 2011-03-30 |
| Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation cyclosporine, cyclosporine and methotrexate - Leukemia, Lymphoma | Phase 3 | Terminated | Baxalta now part of Shire | 105 | 1997-04-01 | 2021-05-06 |
| Treatment of Childhood Acute Lymphoblastic Leukemia asparaginase (E. Coli), asparaginase (Erwina), dexrazoxane - Acute Lymphoblastic Leukemia | Phase 3 | Terminated | Dana-Farber Cancer Institute | 491 | 1996-01-01 | 2007-12-28 |
| Chemotherapy With or Without Total-Body Irradiation Prior to Bone Marrow Transplantation in Treating Children With Acute Lymphoblastic Leukemia cyclophosphamide, cyclosporine, etoposide - Leukemia | Phase 3 | Terminated | Children's Hospital of Philadelphia | 43 | 1995-10-01 | 2013-10-16 |
Leukemia (8) · Myelodysplastic Syndromes (6) · Graft vs Host Disease (5) · Leukemia, Myeloid, Acute (5) · Lymphoma (5) · Burkitt Lymphoma (4) · Lymphoma, Large B-Cell, Diffuse (4) · Myeloproliferative Disorders (4) · Hematologic Neoplasms (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Leukemia, Myeloid, Accelerated Phase (3) · Leukemia, Myeloid, Chronic-Phase (3) · Leukemia, Myelomonocytic, Chronic (3) · Lymphoma, B-Cell, Marginal Zone (3)
Hematologic Diseases (18) · Hemic and Lymphatic Diseases (18) · Immune System Diseases (18) · Immunoproliferative Disorders (18) · Leukemia, Lymphoid (18) · Lymphatic Diseases (18) · Lymphoproliferative Disorders (18) · Neoplasms by Histologic Type (18) · Neoplasms (17) · Leukemia (10) · Bone Marrow Diseases (8) · Leukemia, Myeloid (7) · Disease Attributes (6) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6)
Cyclophosphamide (6) · Methotrexate (5) · Etoposide (3) · Vincristine (3) · Asparaginase (2) · Busulfan (2) · Cyclosporine (2) · Doxorubicin (2) · Prednisone (2) · Radiation (2) · Antilymphocyte Serum (1) · Bone Marrow Transplantation (1) · Calcineurin Inhibitors (1) · Cytarabine (1) · Daunorubicin (1)
Kiadis Pharma (2) · M.D. Anderson Cancer Center (2) · Amgen (1) · Baxalta now part of Shire (1) · Children's Hospital of Philadelphia (1) · Dana-Farber Cancer Institute (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Hospital Israelita Albert Einstein (1) · Institut de Recherches Internationales Servier (1) · Martin, Paul (1) · Masonic Cancer Center, University of Minnesota (1) · OHSU Knight Cancer Institute (1) · Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · PETHEMA Foundation (1) · Spectrum Pharmaceuticals, Inc (1)
United States (15) · Canada (6) · Belgium (4) · Germany (3) · Italy (3) · Spain (3) · United Kingdom (3) · Australia (2) · France (2) · Israel (2) · Netherlands (2) · Austria (1) · Brazil (1) · Bulgaria (1) · Croatia (1)
Andrea Velardi, MD (1) · Ching-Hon Pui, MD (1) · Daniel J. DeAngelo, MD, PhD (1) · Denis Claude Roy, Prof MD (1) · Denis-Claude Roy, MD (1) · Joseph Bubalo, PharmD, BCPS, BCOP (1) · Katy Rezvani, MD PhD (1) · Khanh Vu, MD (1) · Marcos de Lima, MD (1) · Margaret MacMillan, MD (1) · Nancy Bunin, MD (1) · Paul J. Martin, MD (1) · Paulo V Campregher, MD (1)
PMID 15226337, PMID 15247354, PMID 19270260, PMID 20850381, PMID 22658895, PMID 32289160, PMID 33026184, PMID 33542479, PMID 34161631, PMID 35622074, PMID 41074700
2016 (1), P30CA069533 (1)